114 related articles for article (PubMed ID: 12735660)
1. A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD.
Cazzola M; Santus P; Matera MG; Carlucci P; Belloli E; Di Marco F; Centanni S
Respir Med; 2003 May; 97(5):458-62. PubMed ID: 12735660
[TBL] [Abstract][Full Text] [Related]
2. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
3. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
Cazzola M; Noschese P; De Michele F; D'Amato G; Matera MG
Respir Med; 2006 Feb; 100(2):212-7. PubMed ID: 15936184
[TBL] [Abstract][Full Text] [Related]
4. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD.
Cazzola M; Di Perna F; D'Amato M; Califano C; Matera MG; D'Amato G
Respir Med; 2001 Nov; 95(11):917-21. PubMed ID: 11716207
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD.
Cazzola M; Califano C; Di Perna F; D'Amato M; Terzano C; Matera MG; D'Amato G; Marsico SA
Respir Med; 2002 Oct; 96(10):790-5. PubMed ID: 12412978
[TBL] [Abstract][Full Text] [Related]
6. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.
van der Woude HJ; Winter TH; Aalbers R
Thorax; 2001 Jul; 56(7):529-35. PubMed ID: 11413351
[TBL] [Abstract][Full Text] [Related]
7. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD.
Derom E; Strandgården K; Schelfhout V; Borgström L; Pauwels R
Respir Med; 2007 Sep; 101(9):1931-41. PubMed ID: 17544264
[TBL] [Abstract][Full Text] [Related]
8. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
9. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
Cazzola M; Mantero A; Santus P; Carlucci P; Mondoni M; Bosotti L; Centanni S
Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
11. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
Cazzola M; Santus P; Di Marco F; Boveri B; Castagna F; Carlucci P; Matera MG; Centanni S
Respir Med; 2003 May; 97(5):453-7. PubMed ID: 12735659
[TBL] [Abstract][Full Text] [Related]
12. Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD.
Cazzola M; Di Perna F; Noschese P; Vinciguerra A; Calderaro F; Girbino G; Matera MG
Eur Respir J; 1998 Jun; 11(6):1337-41. PubMed ID: 9657576
[TBL] [Abstract][Full Text] [Related]
13. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Palmqvist M; Persson G; Lazer L; Rosenborg J; Larsson P; Lötvall J
Eur Respir J; 1997 Nov; 10(11):2484-9. PubMed ID: 9426083
[TBL] [Abstract][Full Text] [Related]
14. Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol in COPD patients.
Cazzola M; Noschese P; Salzillo A; De Giglio C; D'Amato G; Matera MG
Respir Med; 2005 May; 99(5):524-8. PubMed ID: 15823447
[TBL] [Abstract][Full Text] [Related]
15. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline.
Richter K; Janicki S; Jörres RA; Magnussen H
Eur Respir J; 2002 May; 19(5):865-71. PubMed ID: 12030726
[TBL] [Abstract][Full Text] [Related]
16. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
18. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD.
Cazzola M; Matera MG; Di Perna E; Califano C; D'Amato M; Mazzarella G
Respir Med; 1999 Dec; 93(12):909-11. PubMed ID: 10653054
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD.
Quinn D; Seale JP; Reisner C; Fischer T; Golden M; Fernandez C; Darken P; St Rose E; Thomas M; Tardie G; Orevillo C
Respir Med; 2014 Sep; 108(9):1327-35. PubMed ID: 25060541
[TBL] [Abstract][Full Text] [Related]
20. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]